Skip to main content
70°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
477.37
+5.37 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat
February 05, 2024
The company also topped fourth-quarter expectations.
Via
Investor's Business Daily
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
February 05, 2024
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
February 05, 2024
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024.
Via
Benzinga
Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings
February 05, 2024
As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Earnings Preview: Vertex Pharmaceuticals
February 02, 2024
Via
Benzinga
Earnings Scheduled For February 5, 2024
February 05, 2024
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.
Via
Benzinga
Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week
February 05, 2024
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Key Takeaways From Vertex Pharmaceuticals Analyst Ratings
January 31, 2024
Via
Benzinga
Here's My Top Growth Stock to Buy Right Now
January 27, 2024
There doesn't appear to be a weak link with this great stock.
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
January 25, 2024
As the adage goes, winners keep winning.
Via
The Motley Fool
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3
February 03, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2.
Via
Talk Markets
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
February 02, 2024
Vertex shares recently reached an all-time high.
Via
The Motley Fool
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Should Quality Investors Include NASDAQ:VRTX in Their Portfolio?
February 02, 2024
In this article we'll explore the quality characteristics of VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)
Via
Chartmill
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
February 01, 2024
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.
Via
InvestorPlace
Biotech And Medtech Portfolio Notes On A Fed Day
January 31, 2024
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Buy Alert: 3 Stocks Sitting in the Sweet Spot
January 31, 2024
They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting.
Via
InvestorPlace
Why Vertex Pharmaceuticals Stock Topped the Market Today
January 30, 2024
The company reported that it met its primary endpoint in a study for its non-opioid pain drug.
Via
The Motley Fool
Why Is Vertex Pharmaceuticals Stock Sliding Today?
January 30, 2024
Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.
Via
Benzinga
Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst
January 30, 2024
The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal.
Via
Investor's Business Daily
Is CRISPR Therapeutics a Buy in the New Bull Market?
January 30, 2024
CRISPR Therapeutics is a specialist in the hot technology of gene editing.
Via
The Motley Fool
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
January 29, 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
It's always tough to be compared to a giant.
Via
The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
January 24, 2024
The company could maintain the momentum it gained last year.
Via
The Motley Fool
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
January 24, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today
January 24, 2024
These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.